VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2024 15:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

01 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

11 Jun 2024 15:01:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

07 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

25 May 2024 08:40:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

09 May 2024 07:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 May 2024 15:38:19 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

02 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

20 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

28 Feb 2024 15:20:12 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

02 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

01 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

29 Jan 2024 22:50:31 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

29 Jan 2024 05:15:00 By Nasdaq GlobeNewswire

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

25 Jan 2024 05:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

08 Jan 2024 07:01:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

27 Dec 2023 07:00:00 By Nasdaq GlobeNewswire